387 related articles for article (PubMed ID: 11474773)
41. Time-dependent amplified pharmacokinetic and pharmacodynamic responses of rabeprazole in cytochrome P450 2C19 poor metabolizers.
Lin CJ; Yang JC; Uang YS; Chern HD; Wang TH
Pharmacotherapy; 2003 Jun; 23(6):711-9. PubMed ID: 12820812
[TBL] [Abstract][Full Text] [Related]
42. Pharmacokinetics of proton pump inhibitors in children.
Litalien C; Théorêt Y; Faure C
Clin Pharmacokinet; 2005; 44(5):441-66. PubMed ID: 15871633
[TBL] [Abstract][Full Text] [Related]
43. Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans.
Furuta T; Ohashi K; Kobayashi K; Iida I; Yoshida H; Shirai N; Takashima M; Kosuge K; Hanai H; Chiba K; Ishizaki T; Kaneko E
Clin Pharmacol Ther; 1999 Sep; 66(3):265-74. PubMed ID: 10511062
[TBL] [Abstract][Full Text] [Related]
44. Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs.
Meyer UA
Eur J Gastroenterol Hepatol; 1996 Oct; 8 Suppl 1():S21-5. PubMed ID: 8930576
[TBL] [Abstract][Full Text] [Related]
45. [Tailor-made medicine in Helicobacter pylori eradication therapy].
Aoyama N; Shirasaka D; Miki I
Nihon Rinsho; 2003 Jan; 61(1):129-36. PubMed ID: 12607330
[TBL] [Abstract][Full Text] [Related]
46. [Recent topics on important drugs for H. pylori eradication: Rabeprazole].
Sugimoto M; Furuta T; Nakmura A; Shirai N
Nihon Rinsho; 2005 Nov; 63 Suppl 11():350-3. PubMed ID: 16363558
[No Abstract] [Full Text] [Related]
47. Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine.
Miura M; Tada H; Yasui-Furukori N; Uno T; Sugawara K; Tateishi T; Suzuki T
Br J Clin Pharmacol; 2005 Jul; 60(1):61-8. PubMed ID: 15963095
[TBL] [Abstract][Full Text] [Related]
48. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
Li XQ; Andersson TB; Ahlström M; Weidolf L
Drug Metab Dispos; 2004 Aug; 32(8):821-7. PubMed ID: 15258107
[TBL] [Abstract][Full Text] [Related]
49. Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes.
Yasui-Furukori N; Saito M; Uno T; Takahata T; Sugawara K; Tateishi T
J Clin Pharmacol; 2004 Nov; 44(11):1223-9. PubMed ID: 15496639
[TBL] [Abstract][Full Text] [Related]
50. Optimal dose of omeprazole for CYP2C19 extensive metabolizers in anti-Helicobacter pylori therapy: pharmacokinetic considerations.
Kita T; Sakaeda T; Aoyama N; Sakai T; Kawahara Y; Kasuga M; Okumura K
Biol Pharm Bull; 2002 Jul; 25(7):923-7. PubMed ID: 12132671
[TBL] [Abstract][Full Text] [Related]
51. Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole.
Furuta T; Shirai N; Watanabe F; Honda S; Takeuchi K; Iida T; Sato Y; Kajimura M; Futami H; Takayanagi S; Yamada M; Ohashi K; Ishizaki T; Hanai H
Clin Pharmacol Ther; 2002 Oct; 72(4):453-60. PubMed ID: 12386647
[TBL] [Abstract][Full Text] [Related]
52. Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data.
Schwab M; Klotz U; Hofmann U; Schaeffeler E; Leodolter A; Malfertheiner P; Treiber G
Clin Pharmacol Ther; 2005 Dec; 78(6):627-34. PubMed ID: 16338278
[TBL] [Abstract][Full Text] [Related]
53. New-generation proton pump inhibitors: overcoming the limitations of early-generation agents.
Robinson M
Eur J Gastroenterol Hepatol; 2001 May; 13 Suppl 1():S43-7. PubMed ID: 11430508
[TBL] [Abstract][Full Text] [Related]
54. A comparative study on endoscopic ulcer healing of omeprazole versus rabeprazole with respect to CYP2C19 genotypic differences.
Ando T; Kato H; Sugimoto N; Nagao Y; Seto N; Hongo H; Kajikawa H; Isozaki Y; Shimozawa M; Naito Y; Yoshida N; Ishizaki T; Yoshikawa T
Dig Dis Sci; 2005 Sep; 50(9):1625-31. PubMed ID: 16133961
[TBL] [Abstract][Full Text] [Related]
55. Comparison of the effect on intragastric pH of a single dose of omeprazole or rabeprazole: which is suitable for on-demand therapy?
Inamori M; Togawa J; Takahashi K; Yoneda M; Fujisawa N; Iwasaki T; Ozawa Y; Kikuchi T; Muramatsu K; Chiguchi G; Matsumoto S; Kawamura H; Abe Y; Kirikoshi H; Kobayashi N; Sakaguchi T; Takamura T; Nakajima A; Ueno N; Sekihara H
J Gastroenterol Hepatol; 2003 Sep; 18(9):1034-8. PubMed ID: 12911659
[TBL] [Abstract][Full Text] [Related]
56. Efficacy of low-dose proton pump inhibitor (PPI) in the eradication of Helicobacter pylori following combination PPI/AC therapy in Japan.
Kawai T; Kawakami K; Mikinori K; Takei K; Itoi T; Moriyasu F; Takagi Y; Aoki T; Watanebe K; Matsumoto Y; Rimbara E; Noguchi N; Sasatsu M
Hepatogastroenterology; 2007 Mar; 54(74):649-54. PubMed ID: 17523342
[TBL] [Abstract][Full Text] [Related]
57. [Cytochrome P450 2C19 genotype -based second line therapy with amoxicillin and lansoprazole after failure of initial helicobacter pylori eradication therapy].
Asano M; Taniwaki H; Tsuji D; Sato Y; Shimizu T
Nihon Rinsho; 2005 Dec; 63 Suppl 12():450-3. PubMed ID: 16416832
[No Abstract] [Full Text] [Related]
58. Effect of clarithromycin on the enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes.
Miura M; Tada H; Yasui-Furukori N; Uno T; Sugawara K; Tateishi T; Suzuki T
Chirality; 2005 Jun; 17(6):338-44. PubMed ID: 15856433
[TBL] [Abstract][Full Text] [Related]
59. Pharmacokinetic interactions between omeprazole/pantoprazole and clarithromycin in health volunteers.
Calabresi L; Pazzucconi F; Ferrara S; Di Paolo A; Tacca MD; Sirtori C
Pharmacol Res; 2004 May; 49(5):493-9. PubMed ID: 14998561
[TBL] [Abstract][Full Text] [Related]
60. Drug interaction of tacrolimus and proton pump inhibitors in renal transplant recipients with CYP2C19 gene mutation.
Itagaki F; Homma M; Yuzawa K; Fukao K; Kohda Y
Transplant Proc; 2002 Nov; 34(7):2777-8. PubMed ID: 12431607
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
